Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

Author(s):

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago

This episode addresses strategies for mitigating and managing adverse events associated with Dato-DXd in patients with advanced NSCLC, explores how the drug’s structure may help prevent acquired resistance mechanisms that are common with TKIs, and discusses the broader implications of integrating Dato-DXd and other ADCs into the treatment landscape for this patient population.

EP: 1.Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP: 2.Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP: 3.ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP: 4.Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

EP: 5.Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

EP: 6.Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

EP: 7.Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

EP: 8.Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

EP: 9.Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

Now Viewing

EP: 10.Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

EP: 11.Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

EP: 12.Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

EP: 13.Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02

EP: 14.Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

Video content above is prompted by the following:

How would you mitigate or manage grade >3 Dato-DXd–related adverse events among your patients with advanced or metastatic NSCLC?
How might the structure and function of Dato-DX-d deter the development of acquired resistance mechanisms observed with TKIs in this AGA population?
How does the armamentarium expand here?